SOPHiA GENETICS SA (SOPH) Misses Q4 EPS by 2c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts SOPH Hot Sheet
Join SI Premium – FREE
SOPHiA GENETICS SA (NASDAQ: SOPH) reported Q4 EPS of ($0.23), $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $17.84 million.
GUIDANCE:
SOPHiA GENETICS SA sees FY2025 revenue of $72-76 million, versus the consensus of $74.512 million. Adjusted EBITDA loss between $35 million and $39 million, compared to $40.2 million in FY 2024
For earnings history and earnings-related data on SOPHiA GENETICS SA (SOPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tecnoglass (TGLS) Tops Q3 EPS by 2c ; Offers Guidance
- Filana Therapeutics, Inc. (FLNA) Tops Q3 EPS by 3c
- Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
